Researchers post positive late-stage Heplisav data

Researchers for Dynavax and Merck say that a late-stage trial of their hepatitis B vaccine Heplisav hit the endpoint they were aiming at: non-inferior antibody response compared to GlaxoSmithKline's Engerix-B. The vaccine is being studied as a treatment for end stage renal disease. Altogether 95 percent of the Heplisav group developed HBV antibodies compared to 81 percent of the Engerix-B group. Dynavax shares surged about 11 percent on the news.

The FDA had placed a clinical hold on the Heplisav work earlier in the year after a patient developed symptoms of an autoimmune disease. And BioWorld notes that the hold--which is ongoing--has interrupted research needed to support the companies' BLA. Pressed by analysts, Dynavax CEO Dino Dina declined to lay out a timeline for responding to the FDA or when he expects the hold to be lifted.  

- here's the release
- read the report on Heplisav

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.